Drug
18F-FSPG
18F-FSPG is a pharmaceutical drug with 6 clinical trials. Historical success rate of 50.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 3 completed trials
Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
3(50%)
Phase Distribution
Ph early_phase_1
1
17%
Ph phase_2
4
67%
Ph phase_1
1
17%
Phase Distribution
2
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
3 of 6 finished
Non-Completion Rate
50.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(3)
Terminated(3)
Detailed Status
Terminated3
Completed3
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 24 (66.7%)
Trials by Status
terminated350%
completed350%
Recent Activity
0 active trials
Showing 5 of 6
terminatedearly_phase_1
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
NCT05322135
completedphase_2
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
NCT04488094
terminatedphase_2
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
NCT03103490
completedphase_2
Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease
NCT03546868
completedphase_2
18F-FSPG PET/CT for Cancer Patients on Therapy
NCT02599194
Clinical Trials (6)
Showing 6 of 6 trials
NCT05322135Early Phase 1
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
NCT04488094Phase 2
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
NCT03103490Phase 2
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
NCT03546868Phase 2
Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease
NCT02599194Phase 2
18F-FSPG PET/CT for Cancer Patients on Therapy
NCT02370563Phase 1
PET Imaging of Intracranial Cancers With 18F-FSPG
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6